{"title":"用于惩罚性回归正则化参数选择的新型广义信息准则,并将其应用于治疗过程数据。","authors":"Amir Hossein Ghatari, Mina Aminghafari","doi":"10.1080/10543406.2023.2228399","DOIUrl":null,"url":null,"abstract":"<p><p>We propose a new approach to select the regularization parameter using a new version of the generalized information criterion (<math><mi>GIC</mi></math>) in the subject of penalized regression. We prove the identifiability of bridge regression model as a prerequisite of statistical modeling. Then, we propose asymptotically efficient generalized information criterion (<math><mi>AGIC</mi></math>) and prove that it has asymptotic loss efficiency. Also, we verified the better performance of <math><mi>AGIC</mi></math> in comparison to the older versions of <math><mi>GIC</mi></math>. Furthermore, we propose <math><mi>MSE</mi></math> search paths to order the selected features by lasso regression based on numerical studies. The <math><mi>MSE</mi></math> search paths provide a way to cover the lack of feature ordering in lasso regression model. The performance of <math><mi>AGIC</mi></math> with other types of <math><mi>GIC</mi></math> is compared using <math><mi>MSE</mi></math> and model utility in simulation study. We exert <math><mi>AGIC</mi></math> and other criteria to analyze breast and prostate cancer and Parkinson disease datasets. The results confirm the superiority of <math><mi>AGIC</mi></math> in almost all situations.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"488-512"},"PeriodicalIF":1.2000,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A new type of generalized information criterion for regularization parameter selection in penalized regression with application to treatment process data.\",\"authors\":\"Amir Hossein Ghatari, Mina Aminghafari\",\"doi\":\"10.1080/10543406.2023.2228399\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We propose a new approach to select the regularization parameter using a new version of the generalized information criterion (<math><mi>GIC</mi></math>) in the subject of penalized regression. We prove the identifiability of bridge regression model as a prerequisite of statistical modeling. Then, we propose asymptotically efficient generalized information criterion (<math><mi>AGIC</mi></math>) and prove that it has asymptotic loss efficiency. Also, we verified the better performance of <math><mi>AGIC</mi></math> in comparison to the older versions of <math><mi>GIC</mi></math>. Furthermore, we propose <math><mi>MSE</mi></math> search paths to order the selected features by lasso regression based on numerical studies. The <math><mi>MSE</mi></math> search paths provide a way to cover the lack of feature ordering in lasso regression model. The performance of <math><mi>AGIC</mi></math> with other types of <math><mi>GIC</mi></math> is compared using <math><mi>MSE</mi></math> and model utility in simulation study. We exert <math><mi>AGIC</mi></math> and other criteria to analyze breast and prostate cancer and Parkinson disease datasets. The results confirm the superiority of <math><mi>AGIC</mi></math> in almost all situations.</p>\",\"PeriodicalId\":54870,\"journal\":{\"name\":\"Journal of Biopharmaceutical Statistics\",\"volume\":\" \",\"pages\":\"488-512\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-07-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Biopharmaceutical Statistics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10543406.2023.2228399\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/7/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2023.2228399","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/17 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
A new type of generalized information criterion for regularization parameter selection in penalized regression with application to treatment process data.
We propose a new approach to select the regularization parameter using a new version of the generalized information criterion () in the subject of penalized regression. We prove the identifiability of bridge regression model as a prerequisite of statistical modeling. Then, we propose asymptotically efficient generalized information criterion () and prove that it has asymptotic loss efficiency. Also, we verified the better performance of in comparison to the older versions of . Furthermore, we propose search paths to order the selected features by lasso regression based on numerical studies. The search paths provide a way to cover the lack of feature ordering in lasso regression model. The performance of with other types of is compared using and model utility in simulation study. We exert and other criteria to analyze breast and prostate cancer and Parkinson disease datasets. The results confirm the superiority of in almost all situations.
期刊介绍:
The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers:
Drug, device, and biological research and development;
Drug screening and drug design;
Assessment of pharmacological activity;
Pharmaceutical formulation and scale-up;
Preclinical safety assessment;
Bioavailability, bioequivalence, and pharmacokinetics;
Phase, I, II, and III clinical development including complex innovative designs;
Premarket approval assessment of clinical safety;
Postmarketing surveillance;
Big data and artificial intelligence and applications.